Lipoprotein-like phospholipid particles inhibit the smooth muscle cell cytotoxicity of lysophosphatidylcholine and platelet-activating factor

Arteriosclerosis, Thrombosis, and Vascular Biology
J NilssonP K Shah

Abstract

Oxidation of LDL is associated with degradation of phosphatidylcholine into platelet-activating factor (PAF)-like phospholipids and lysophosphatidylcholine (LPC). Exposure of cultured human smooth muscle cells to PAF and LPC in a concentration of 25 micromol/L was found to result in complete cell death, as assessed by the MTT cytotoxicity assay and cell counting. Addition of 50 microg/mL apolipoprotein A-I- and apolipoprotein A-I(Milano)-containing phospholipid particles completely inhibited this cytotoxicity. Phospholipid complexes alone were almost as effective, whereas free apolipoprotein A-I(Milano) and albumin were without effect, suggesting that the effect was phospholipid dependent. Experiments using [14C]LPC demonstrated that apolipoprotein A-I- and apolipoprotein A-I(Milano)-containing phospholipid particles effectively bind LPC. The results show that HDL-like phospholipid particles effectively inhibit the toxic effect of phospholipids and other lipid-soluble factors. The ability of HDL to inhibit the proinflammatory and toxic effects of phospholipids generated during oxidation of LDL may be responsible for part of the antiatherogenic properties of HDL.

References

Jul 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·Y AsaokaY Nishizuka
Dec 1, 1991·The Journal of Clinical Investigation·J L Witztum, D Steinberg
Dec 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·S Parthasarathy, J Barnett
May 22, 1990·Biochimica Et Biophysica Acta·S ParthasarathyL G Fong
Jan 1, 1986·Methods in Enzymology·M C Cheung
Jun 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·U P SteinbrecherD Steinberg
Nov 22, 1994·Proceedings of the National Academy of Sciences of the United States of America·G M ChisolmP E DiCorleto
Aug 1, 1994·The Journal of Clinical Investigation·C PásztyE M Rubin
Nov 1, 1993·The Journal of Surgical Research·R A KozarH J Pownall
Feb 1, 1994·Proceedings of the National Academy of Sciences of the United States of America·T NakanoR Ross
Jun 11, 1996·Biochimica Et Biophysica Acta·D M StafforiniT M McIntyre

❮ Previous
Next ❯

Citations

Mar 3, 2006·Current Atherosclerosis Reports·Laura CalabresiGuido Franceschini
Jan 18, 2003·Biochimica Et Biophysica Acta·Robert SalvayreAnne Negre-Salvayre
Jul 27, 2007·Proceedings of the National Academy of Sciences of the United States of America·Donna L PedicordYuval Blat
Feb 11, 2005·Omics : a Journal of Integrative Biology·Eugene DavidovStephen Naylor
Mar 1, 2006·Expert Opinion on Investigational Drugs·Marta Marchesi, Cesare R Sirtori
Jun 13, 2008·Biochemical Pharmacology·Carlos G Santos-GallegoJuan J Badimon

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.